http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 04:08:47 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Mizuho+Starts+Century+Therapeutics+%28IPSC%29+at+Outperform/26552439.html (Updated - May 27, 2026 4:08 AM EDT) <p>Mizuho analyst Salim Syed initiates coverage on Century Therapeutics (NASDAQ: IPSC) with a Outperform rating and a price target of $8.00.</p><p>The analyst commented: "We are initiating coverage of Century Therapeutics with an Outperform (OP) rating and an $8 price target ==> Potentially Curative Cell Therapy for Type 1 Diabetes; Underappreciated Validation and Maturity for Its Stage. Why now? ~2 million people in the US live with T1D. While modern insulin replacement and glucose monitoring are life-sustaining, they serve only as daily management strategies rather than a cure. This leaves a critical unmet need, http://www.streetinsider.com/New+Coverage/Mizuho+Starts+Century+Therapeutics+%28IPSC%29+at+Outperform/26552439.html Wed, 27 May 2026 04:08:47 -0400 IPSC http://www.streetinsider.com/Analyst+Comments/Mizuho+Starts+Century+Therapeutics+%28IPSC%29+at+Outperform/26552439.html (Updated - May 27, 2026 4:08 AM EDT) <p>Mizuho analyst Salim Syed initiates coverage on Century Therapeutics (NASDAQ: IPSC) with a Outperform rating and a price target of $8.00.</p><p>The analyst commented: "We are initiating coverage of Century Therapeutics with an Outperform (OP) rating and an $8 price target ==> Potentially Curative Cell Therapy for Type 1 Diabetes; Underappreciated Validation and Maturity for Its Stage. Why now? ~2 million people in the US live with T1D. While modern insulin replacement and glucose monitoring are life-sustaining, they serve only as daily management strategies rather than a cure. This leaves a critical unmet need, http://www.streetinsider.com/Analyst+Comments/Mizuho+Starts+Century+Therapeutics+%28IPSC%29+at+Outperform/26552439.html Wed, 27 May 2026 04:08:47 -0400 IPSC http://www.streetinsider.com/SEC+Filings/Form++424B7++++++Century+Therapeutics%2C++++++++++++++++/26536548.html si-local-file:///var/storage/secattach/20260521/26536548.html http://www.streetinsider.com/SEC+Filings/Form++424B7++++++Century+Therapeutics%2C++++++++++++++++/26536548.html Thu, 21 May 2026 17:02:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++424B7++++++Century+Therapeutics%2C++++++++++++++++/26536548.html si-local-file:///var/storage/secattach/20260521/26536548.html http://www.streetinsider.com/SEC+Filings/Form++424B7++++++Century+Therapeutics%2C++++++++++++++++/26536548.html Thu, 21 May 2026 17:02:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+May+15++Filed+by%3A+Pfeiffenberger+Brent/26521204.html si-local-file:///var/storage/secattach/20260519/26521204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+May+15++Filed+by%3A+Pfeiffenberger+Brent/26521204.html Tue, 19 May 2026 16:10:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+May+15++Filed+by%3A+Pfeiffenberger+Brent/26521204.html si-local-file:///var/storage/secattach/20260519/26521204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Century+Therapeutics%2C+++++For%3A+May+15++Filed+by%3A+Pfeiffenberger+Brent/26521204.html Tue, 19 May 2026 16:10:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506150.html si-local-file:///var/storage/secattach/20260515/26506150.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506150.html Fri, 15 May 2026 16:27:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506150.html si-local-file:///var/storage/secattach/20260515/26506150.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506150.html Fri, 15 May 2026 16:27:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499929.html si-local-file:///var/storage/secattach/20260515/26499929.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499929.html Fri, 15 May 2026 08:15:00 -0400 IPSC O.40693967 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499929.html si-local-file:///var/storage/secattach/20260515/26499929.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Century+Therapeutics%2C++++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26499929.html Fri, 15 May 2026 08:15:00 -0400 IPSC O.40693967 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html <p>Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Brent Pfeiffenberger to its board of directors, the clinical-stage company announced.</p> <p>Pfeiffenberger currently serves as president and chief executive officer of Century Therapeutics (NASDAQ: IPSC) and chairs its board. He previously worked as chief operating officer at Neogene Therapeutics, where he helped transform the company from preclinical to clinical-stage operations before its acquisition by AstraZeneca in 2023.</p> <p>Before joining Neogene, Pfeiffenberger spent nearly two decades at Bristol Myers Squibb in various leadership roles, most recently as senior vice president and head of U.S. oncology, overseeing operations for the multi-billion-dollar franchise. He holds a PharmD from http://www.streetinsider.com/Board+Changes/Corbus+Pharmaceuticals+names+Brent+Pfeiffenberger+to+board+of+directors/26490344.html Thu, 14 May 2026 08:01:20 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html <p align="justify">NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Board of Directors.</p> <p align="justify">“Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs,” said Rachelle Jacques, Chair of the Corbus Board of Directors. “His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Brent’s http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html Thu, 14 May 2026 08:00:00 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html <p align="justify">NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Board of Directors.</p> <p align="justify">“Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs,” said Rachelle Jacques, Chair of the Corbus Board of Directors. “His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Brent’s http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html Thu, 14 May 2026 08:00:00 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html <p align="justify">NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Board of Directors.</p> <p align="justify">“Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs,” said Rachelle Jacques, Chair of the Corbus Board of Directors. “His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Brent’s http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html Thu, 14 May 2026 08:00:00 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html <p align="justify">NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Board of Directors.</p> <p align="justify">“Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs,” said Rachelle Jacques, Chair of the Corbus Board of Directors. “His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Brent’s http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html Thu, 14 May 2026 08:00:00 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537 http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html <p align="justify">NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Board of Directors.</p> <p align="justify">“Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs,” said Rachelle Jacques, Chair of the Corbus Board of Directors. “His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Brent’s http://www.streetinsider.com/Press+Releases/Corbus+Pharmaceuticals+Appoints+Pharma+Industry+Veteran+Brent+Pfeiffenberger+to+Board+of+Directors/26490331.html Thu, 14 May 2026 08:00:00 -0400 A.03607790 A.50216726 A.50216777 CRBP IPSC O.20147506 O.21612337 O.22488230 O.40693967 O.54516537